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Chimpanzees represent the only animal model for studies of the natural history of hepatitis C virus (HCV).
To generate virus stocks of important HCV variants, we infected chimpanzees with HCV strains of genotypes
1–6 and determined the infectivity titer of acute-phase plasma pools in additional animals. The courses of
first- and second-passage infections were similar, with early appearance of viremia, HCV RNA titers of 1104.7
IU/mL, and development of acute hepatitis; the chronicity rate was 56%. The challenge pools had titers of
103–105 chimpanzee infectious doses/mL. Human liver–chimeric mice developed high-titer infections after
inoculation with the challenge viruses of genotypes 1–6. Inoculation studies with different doses of the genotype
1b pool suggested that a relatively high virus dose is required to consistently infect chimeric mice. The challenge
pools represent a unique resource for studies of HCV molecular virology and for studies of pathogenesis,
protective immunity, and vaccine efficacy in vivo.
The most recent estimates suggest that 180 million peo-
ple worldwide are infected with hepatitis C virus
(HCV). In the United States, a total of ∼3.2 million
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people are persistently infected with HCV, and 110,000
people die from HCV-related chronic liver disease each
year. A continued increase in the number of HCV-
infected patients with liver cirrhosis and hepatocellular
carcinoma is expected during the next few decades, and
HCV-associated end-stage liver disease is already the
most common indication for liver transplantation in
many Western countries. Thus, there is an urgent need
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for better drugs to treat this disease and for the development
of a vaccine to prevent further spread. To promote such de-
velopments, it is important to define the pathogenesis of dif-
ferent HCV genotypes in available animal models and to de-
velop well-characterized virus stocks that represent the various
HCV variants that can be used in the development of new
experimental in vitro systems and for in vivo studies of new
drugs and passive and active immunization strategies.
The HCV virion contains a positive-sense, single-stranded
RNA genome that has a single long open reading frame (ORF)
[1, 2]. Extensive genomic sequence analysis has demonstrated
that HCV strains from around the world exhibit significant
genetic heterogeneity, and on the basis of phylogenetic analysis
of the ORF of representative isolates, HCV has been classified
into 6 major genotypes (genotypes 1–6) and a number of sub-
types (subtypes a, b, and so forth) [3–5]. Important differences
in the geographic distribution of these genotypes exist, and
recent studies have suggested important antigenic and serologic
differences [2]. Furthermore, it is well established that the cur-
rent standard therapy with interferon and ribavirin has a higher
sustained virologic response rate in patients infected with ge-
notypes 2 and 3, compared with patients infected with geno-
types 1 and 4 [2]. A seventh major genotype has recently been
identified in 3 Canadian and Belgian patients, who were pre-
sumably infected in Central Africa [6]. However, samples from
these patients have not been readily available, and experimental
infection with this new genotype could therefore not be in-
cluded in the present study.
The chimpanzee remains the only animal model that can be
used for studies of the natural history of HCV and in challenge
studies (eg, studies of immunogenicity and efficacy of HCV
vaccine candidates) [7–9]. Despite the recent development of
the strain JFH1 cell culture system, which permits virus prop-
agation of a particular genotype 2a isolate in Huh7.5 cells [10],
there is still no reproducible cell culture system based on the
full-length sequence of other HCV genotype viruses. Thus,
transmission to chimpanzees has been the only means to prop-
agate experimentally HCV viruses of different strains.
Urokinase-type plasminogen activator (uPA)–severe com-
bined immunodeficient (SCID) mice engrafted with primary
human hepatocytes (chimeric mice) are susceptible to infection
with native HCV, and they produce infectious virions with a
density similar to that observed in humans and experimentally
infected chimpanzees [11–13]. This small animal model has
been successfully used to assess the activity of antiviral com-
pounds [14] and to evaluate protection and passive immuni-
zation studies of HCV [15–17], but because of the lack of an
immune system, this model has not been useful for studies of
HCV pathogenesis. Furthermore, this model has not permitted
the generation of large quantities of reagents for studies of these
specific genotypes.
Our aim was to generate titrated challenge pools for the
major HCV genotypes and important subtypes. Challenge vi-
ruses of genotypes 1–6 were characterized in chimpanzees and
in human liver–chimeric mice.
MATERIALS AND METHODS
The housing and care of the chimpanzees were in compliance
with all relevant guidelines and requirements, and the animals
were housed in facilities that are fully accredited by the As-
sociation for Assessment and Accreditation of Laboratory An-
imal Care International. The chimpanzees used were naive for
HCV infection, because they were raised in captivity under
stringent conditions of infectious disease control and housed
in a facility with Animal Biosafety Level 2–3 containment, with
close monitoring for HCV infection as well as for infection
with other hepatitis viruses. Chimpanzees were inoculated in-
travenously with serum samples collected from patients infected
with well-characterized HCV strains [3, 18–21] (Table 1); the
HC-J4/91 (genotype 1b) inoculum was from an experimentally
infected chimpanzee [22]. The 6a strain that resulted in active
experimental HCV infection had not been previously charac-
terized; this strain originated from a patient from Hong Kong
with persistent HCV infection. During the acute HCV infection
in the chimpanzees, plasmapheresis units were collected weekly
and subsequently used to prepare a 1150-mL virus pool for
each genotype strain. To verify the genotype of the infecting
agent, the core-E1 sequence of the recovered virus was deter-
mined as described elsewhere [23]. The HCV infectivity titer
of 1.1-mL aliquots (stored at 80C) of the plasma pools of
genotypes 1–6 was determined by means of reverse titration in
additional chimpanzees, as described elsewhere [24] (Table 2).
Serum samples were collected weekly from inoculated chim-
panzees and examined for HCV antibodies (enzyme-linked im-
munosorbent assay 2.0; Abbott) and alanine aminotransferase
(Anilytics). Initially, the infection status was determined in a
highly sensitive 5′ untranslated region–based reverse transcrip-
tion–nested polymerase chain reaction assay for HCV RNA
detection [24], and in selected samples the HCV RNA titer was
determined by means of reverse transcription–nested poly-
merase chain reaction on serial HCV RNA dilutions, by means
of a Monitor 1.0 and/or Monitor 2.0 assay (Roche Diagnostics),
by means of Versant HCV RNA branched-chain DNA 2.0 and/
or branched-chain DNA 3.0 assay (Bayer), and by means of a
quantitative 5′ untranslated region–based TaqMan assay devel-
oped in house [25]. In most animals, weekly liver biopsy spec-
imens were collected and examined for necroinflammatory
changes (graded as 0 [normal], 1 [mild], 2 [mild-moderate],
3 [moderate-severe], or 4 [severe]).
To generate human liver–chimeric mice, SCID mice that were
homozygous for the uPA-transgene were transplanted with
cryopreserved human hepatocytes from a single HCV-unin-
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Table 2. Standardized Acute-Phase Chimpanzee Pools of Hepatitis C Virus (HCV) Genotypes 1–6
HCV strain Genotype Chimpanzee ID
Weeks when
plasma units
were collected
HCV genome titer,a
log10 IU/mL
Chimpanzee
infectious titer,b
log10 CIDs/mL
H77Cc 1a 1530 7, 8, 9 4.8 3.5
HC-TN 1a 1422 4, 5, 6 5.3 5
HC-J4/91 1b 1410 2, 3, 4, 5, 6 4.7 3
HC-J6 2a 1417 2, 3, 4, 5, 6 5.0 4
HC-J8 2b 1497 1, 2, 5 4.6 4
S52 3a 88A04 2, 3, 4, 5, 6 4.3 3
ED43 4a 1563 3, 4, 5, 6 5.6 5
SA13 5a 1516 1, 2, 3, 4, 5, 6 5.1 4
HK-6a 6a F15 2, 4 4.9 3
a Determined with the Monitor 2.0 assay (Roche).
b Determined by means of reverse titration in 2 chimpanzees (for strain H77C) or in 1 chimpanzee. CID, chimpanzee
infectious dose.
c Monoclonal virus pool collected from CH1530 after intrahepatic transfection with RNA transcripts from clone pCV-H77C.
It is included for comparison.
fected female donor, as described elsewhere [13]; however, the
mice inoculated with HC-J4 (genotype 1b) had been trans-
planted with fresh hepatocytes from other donors [13]. The
animals used in the present study had a human albumin content
of 12 mg/mL (a human albumin content of 11 mg/mL is gen-
erally accepted as evidence for a high-quality human liver graft).
The mice were injected intraperitoneally with defined doses of
the HCV challenge pools (Table 3). The study protocol was
approved by the animal ethics committee of the Ghent Uni-
versity Faculty of Medicine and Health Sciences. Collected
mouse plasma samples were analyzed for human albumin levels
with a human albumin enzyme-linked immunosorbent assay
quantitation kit (Bethyl Laboratories) and for HCV RNA titers
with the Monitor 2.0 assay or the TaqMan48 assay (Roche
Diagnostics).
RESULTS
In 1992, in the absence of culture systems to propagate and
titrate HCV, we initiated a study to generate challenge pools
of the different genotypes of HCV by inoculating naive chim-
panzees with serum containing well-characterized HCV iso-
lates. We have achieved robust infection of chimpanzees with
strains HC-TN (1a), HC-J4 (1b), HC-J6 (2a), HC-J8 (2b), S52
(3a), ED43 (4a), SA13 (5a), and HK-6a (6a). We previously
reported on the genotype 1a and 5a infections [24, 26]. The
first inoculation with HC-J8 (2b) resulted in suboptimal HCV
titers (data not shown), and therefore the infection reported
below resulted from inoculation of a second animal; both an-
imals developed a persistent infection. In all other cases, the
reported infection was the result of the first inoculation per-
formed. However, it should be noted that a number of inoc-
ulations with other HCV strains (S83 [2c], Z4 [4b], Z7 [4c],
DK13 [4d], SA1 [5a], SA7 [5a], and HK2 [6a]) [3] did not
result in infections, most likely because of the presence of neu-
tralizing antibodies in the chronic-phase source samples or be-
cause of suboptimal storage conditions. To our knowledge, this
study permitted for the first time a comparative study of rep-
lication fitness and pathogenicity of the different genotypes of
HCV in chimpanzees.
Experimental infection of chimpanzees with prototype
strains of genotypes 1–6. The 8 chimpanzees inoculated in-
travenously with serum originating from patients infected with
strains of genotypes 1–6 became viremic at week 1 or 2, and
the peak HCV RNA titers were 104.7–105.7 IU/mL (Table 1 and
Figure 1). In the animals infected with genotype 1a, 2a, 5a, or
6a, viral clearance was observed at week 20, 26, and 15 and
after week 30, respectively. In the animals infected with ge-
notype 1b, 2b, 3a, or 4a, the virus persisted for 11 year of
follow-up (Table 1). Thus, the HCV carrier rate in the first-
passage animals was 50%. HCV antibody seroconversion was
observed between weeks 9 and 21; the animal infected with
genotype 6a did not become anti-HCV positive. Finally, all
animals that were evaluated had evidence of acute hepatitis
with elevated liver enzymes (peak serum alanine aminotrans-
ferase levels, 60–744 U/L) and necroinflammatory changes in
liver biopsy specimens (Table 1 and Figure 1); biopsy specimens
were not available from animals CH1563 and CH-F15. It is
noteworthy that in the animals that developed a persistent in-
fection, the HCV RNA titers were relatively low late in the
acute infection (Figure 1), which suggests some viral control.
However, in the 2 animals (CH1410 and CH1563) for which
we had samples that were collected 110 years later, the HCV
RNA titers had increased by 2–3 logs and were similar to or
higher than the peak titers observed during the acute infection
(Table 1).
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Table 3. Infection of Human Liver–Chimeric Mice with Hepatitis C Virus (HCV) Genotypes 1–6 Strains from Titrated Challenge Pools
uPA-SCID
mouse ID
Plasma human
albumin level at
week 0, mg/mL
HCV genotype pool inocula Plasma HCV RNA titer by week, log10 IU/mL
Genotype Strain
Dose,a
log10 CID
Dose,
log10 IU 1 2 3 4 5 6 7 8 Test used
K202 5.2 1a H77C 2.6 3.9 NA 7.7 NA NA NA NA NA NA T
K230 4.0 1a H77C 2.6 3.9 NA 7.7 NA NA NA NA NA NA T
K292 2.2 1a H77C 2.6 3.9 NA 7.8 NA NA NA NA NA NA T
K292R 2.7 1a H77C 2.6 3.9 NA 7.6 NA NA NA NA NA NA T
K16R 2.1 1b HC-J4 1.3 3.0 NA 6.4 NA 7.9 NA 7.5 NA NA M
K21L 7.4 1b HC-J4 1.7 3.4 NA 12.7 NA NA NA NA NA NA M
K7 2.8 1b HC-J4 2.0 3.7 NA 12.7 NA NA NA 7.9 NA NA M
K7L 3.0 1b HC-J4 2.0 3.7 NA 12.7 NA NA NA 7.9 NA 7.2 M
K179-L 4.7 2a HC-J6 3.0 4.0 NA NA 7.4 NA 6.5 NA 5.9 4.9 M
K637 2.1 2b HC-J8 3.0 3.6 !2.9 +b 4.1 5.3 5.6 5.3 5.1 NA T
K595 6.4 3a S52 2.0 3.3 4.6 6.0 6.6 6.5 6.6 6.2 5.9 NA T
K328-R 6.2 4a ED43 3.6 4.2 NA 7.4 NA + + NA NA NA T
K698 2.6 5a SA13 3.0 4.1 +b 4.5 4.8 5.4 NA NA NA NA T
K686 4.6 6a HK-6a 2.0 3.9 NA 4.0 6.2 7.1 7.2 NA NA NA T
NOTE. Plus signs indicate unquantified positive detections of HCV RNA. Uninfected mice are not shown (see text). CID, chimpanzee infectious dose; M,
Roche HCV Monitor 2.0 assay; NA, not available; T, Roche HCV TaqMan48 assay; uPA-SCID, urokinase-type plasminogen activator–severe combined
immunodeficient.
a The titer in CIDs is the titer listed in Table 2, corrected to reflect the relative amount of the inoculum.
b HCV RNA level, !1500 IU/mL.
Preparation and titration of challenge pools of HCV ge-
notypes 1–6. For each genotype, a pool was made from plas-
mapheresis units obtained from infected chimpanzees during
the first 6 weeks of follow-up prior to anti-HCV seroconversion
(Table 2). Plasma units were thawed and pooled on ice and
divided into 1.1-mL aliquots; at least 100 aliquots were prepared
from each pool. For each pool, the genotype strain was initially
confirmed by means of sequence analysis of core-E1 (data not
shown). In other studies, the complete consensus ORF sequence
was determined for viruses recovered from the pools of ge-
notypes 1a, 1b, 2a, and 5a (GenBank accession no. AF177036,
AF054247, EF621489, and AF064490, respectively) [24, 26–28],
and the core-NS2 sequence was determined for viruses recov-
ered from the pools of genotypes 2b, 3a, 4a, and 6a (GenBank
accession no. FJ230882, EU204645, EU363760, and FJ230883,
respectively) [29–32].
The HCV genome titers of the different pools were 104.3–
105.6 IU/mL [25] (Table 2). Most importantly, the infectious
titer of each genotype pool was determined by means of reverse
titration in a naive chimpanzee. For each dilution tested, we
used a new pool aliquot and made dilutions in preinoculation
plasma from the chimpanzee. Typically, 2 or 3 higher dilutions
were tested before the animal became infected. The infectious
titer determined for the pools of genotypes 1–6 were 103–105
chimpanzee infectious doses (CIDs)/mL (Table 2). However, it
should be noted that because this titer was determined by
means of reverse titration with 10-fold dilutions in a single
animal, the titer might be 1log10.
The 8 chimpanzees used for reverse titration of the individual
genotype pools became viremic at week 1 or 2, and peak HCV
RNA titers were 104.7–106.6 IU/mL (Table 1). Viral persistence
for 11 year of follow-up was observed in 5 (63%) of the 8
chimpanzees with second-passage infections (Table 1); these
animals seroconverted between weeks 9 and 15. However, the
3 animals with acute resolving infection did not become anti-
HCV positive. Finally, 6 of the 8 animals had evidence of acute
hepatitis with elevated liver enzymes and/or necroinflammatory
changes in liver biopsy specimens (Table 1); biopsy specimens
were not available from animal CH73.
Susceptibility of human liver–uPA-SCID mice to HCV of
genotypes 1–6. We inoculated chimeric mice with 102.0–103.6
CIDs of the plasma pools of genotypes 1–6 (Table 3); strain
H77C was used for genotype 1a inoculations. The results of
the infections with genotypes 1a and 1b were reported elsewhere
[13, 16]. For the mice inoculated with genotype 1a, 1b, 2a, 4a,
or 6a, we obtained HCV genome titers of 1107 IU/mL within
the first 4 weeks of follow-up. In the mice inoculated with
genotype 2b, 3a, or 5a, the HCV genome titers reached levels
of 1105.4 IU/mL within the first 5 weeks of follow-up (Table
3). Thus, human liver–chimeric mice can be used for studies
with all the different genotype pool strains that have been de-
veloped in the present study.
Additional studies were performed with the genotype 1b pool
to compare the chimpanzee infectivity in the chimpanzee with
that in the human liver–chimeric mouse. In the 1b pool, the
genome titer was 1.7log10 higher than the infectivity titer de-
Figure 1. Course of first-passage infection with hepatitis C virus (HCV) genotypes 1–6 in chimpanzees. Serum samples collected weekly during 24–
29 weeks of follow-up were tested for HCV RNA by means of in-house reverse transcription–nested polymerase chain reaction (PCR) with 5′ untranslated
region primers and/or by means of quantitative tests (see Materials and Methods) (black rectangles, positive by reverse transcription–nested PCR
and/or quantitative test; white rectangles, negative by reverse transcription–nested PCR). The estimated HCV RNA titers (black circles), determined
by means of an in-house TaqMan assay, were plotted against time; samples below the detection limit of ∼10 IU/mL are shown as not detected (ND).
Anti-HCV antibodies were detected in the second-generation enzyme-linked immunosorbent assay (plus signs, positive detections; minus signs, negative
detections). The shaded area represents serum alanine aminotransferase (ALT) level. Weekly liver biopsy specimens were collected and examined for
necroinflammatory changes (graded as 0 [normal], 1 [mild], 2 [mild-moderate], 3 [moderate-severe], or 4 [severe]).
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termined by means of reverse titration in a single chimpanzee,
which suggests that the determined infectivity titer of this pool
was not overestimated (Table 2). First, we challenged 3 chimeric
mice with 20 CIDs, and only 1 mouse became infected (Table
3). Subsequently, we challenged 2 mice with 50 CIDs, and 1
mouse became infected (Table 3). However, as described above,
challenge with 100 CIDs resulted in robust HCV infection in
both animals tested. All the mice used in this titration study
had human albumin levels of 12 mg/mL, which indicates that
the negative results obtained after challenge with 50 CIDs (1
mouse) and 20 CIDs (2 mice) were not due to suboptimal
human liver grafts. In fact, 2 of the 3 animals that remained
HCV negative after challenge had human albumin levels that
were equal to or higher than those of the mice challenged with
100 CIDs. It is noteworthy that the mouse that became infected
after inoculation with only 20 CIDs had a very robust HCV
infection with peak genome titers at week 4 of 107.9 IU/mL.
Overall, this titration study suggests that the human liver–uPA-
SCID mouse model is less susceptible to HCV infection, com-
pared with chimpanzees (1 mouse infectious dose is equal to
∼50 CIDs), but if infection occurs, the viremia course is ap-
parently not dependent on the virus dose that was used.
Because we used different liver grafts for the studies of hu-
man liver–chimeric uPA-SCID mice, it was of interest to de-
termine whether different grafts have similar susceptibility to
HCV infection. We previously found that mice engrafted with
primary hepatocytes (cryopreserved) from the donor, which
were used for most inoculations in the present study, had a
100% infection rate when inoculated with 104 IU of a mouse-
passaged pool of chimpanzee-derived H77C [16] (Table 3).
Here we found that 5 mice engrafted with hepatocytes (cryo-
preserved) from a new donor (human albumin level, 3) had
robust HCV infection with titers of ∼106 IU (at week 2 or 3)
after inoculation with 104 IU of the same mouse-passaged pool
of chimpanzee-derived H77C. Thus, these data suggested that
the HCV susceptibility of this new liver donor is at least as
good as that observed for the old donor.
DISCUSSION
We have demonstrated and/or confirmed that chimpanzees are
susceptible to all 6 published HCV genotypes and important
subtypes. For many of the genotypes, this is the first time the
course of infection in chimpanzees has been described, to our
knowledge. Overall, we found that the course of acute infection
is similar in animals infected with the different HCV genotypes,
with early appearance of viremia, relatively high peak genome
titers, and development of acute hepatitis. It should be noted,
however, that infection in 2 animals does not necessarily rep-
resent the typical course for a particular genotype or, for that
matter, that particular strain. Also, we cannot rule out the
possibility that the infection observed in animals after reverse
titration could be influenced by exposure to apparently non-
infectious virus challenges. However, we observed robust in-
fections in both first- and second-passage animals, with no
apparent difference. This is in agreement with data previous-
ly published by our group, in which it was found that chimpan-
zees inoculated with high doses (1,000,000 infectious doses
of the H77 strain) of HCV had infections that were similar to
those observed after inoculation with lower doses, only with a
shorter incubation period [33].
The chronicity rate of HCV in experimentally infected chim-
panzees has varied in different studies, from as low as 33% to
as high as 67% [9]. In the present study, we found a chronici-
ty rate of 56% among 16 experimentally infected chimpanzees.
It is noteworthy that in the available samples taken from the
same animals during the late chronic-phase infection (CH1410,
CH1563, and CH1547), there was a clear indication of an in-
crease in viral titers over time, compared with samples taken
from the same animals during the late acute-phase infection
(Table 1 and Figure 1), which suggests a relative loss of the
host’s control of viremia [34]. We observed that 5 of 7 animals
with acute resolving infection did not seroconvert (4 animals)
or had transient seroconversion (1 animal), whereas all 9 an-
imals that developed a persistent infection seroconverted during
the acute infection. Although it must be acknowledged that the
humoral immune response of chimpanzees might differ from
that of humans [35, 36], these data are in agreement with data
from long-term follow-up studies of patients with transfusion-
associated HCV infection [37].
The virus pools characterized in the present study have been
useful for a number of studies with chimpanzees. The chim-
panzee is the only animal model in which to study protective
immunity following resolved experimental infections or im-
munization with vaccine candidates. However, titrated chal-
lenge viruses previously were available only for genotype 1a and
1b strains. The current virus panel has made it possible to
perform more extensive heterologous rechallenges. In a study
by Prince et al [38], in which chimpanzees with resolved ge-
notype 1 infections were rechallenged with 100 CIDs of these
respective genotype pools, it was found that heterologous chal-
lenge would lead to frequent viral persistence. In a recent study,
we found that an animal with apparent sterilizing immunity
against challenge with the homologous genotype 1a was not
protected against acute infection with genotype 1b or 2a after
challenge with 100 CIDs of the respective virus pools [39]. In
the testing of vaccine candidates, it is important to challenge
with a virus dose that consistently infects the animal. Titrated
virus pools of genotype 1a have been important for a number
of vaccine studies with chimpanzees [40]. The 1b pool pre-
sented here has been used in other vaccine studies [41, 42].
The virus-containing plasma pools could also be useful in the
development of diagnostic assays, such as quantitative diag-
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nostic assays or genotyping assays, and they have already been
distributed to a number of investigators for these purposes.
Advances in HCV research have been hampered by a lack
of readily available in vitro systems. The development of in-
fectious HCV clones of strain H77 in 1997 paved the way for
the development of such systems [43, 44]; genotype 1a (pHC-
TN), 1b (pCV-J4L6S), and 2a (pJ6CF) infectious clones have
since been developed from the virus pools characterized in the
present study [26–28]. A subgenomic replicon system for strain
Con1 (genotype 1b) was developed in 1999 [45]; however, this
system currently is available only for genotype 1a, 1b, and 2a
HCV strains. A retroviral pseudoparticle system bearing the
HCV glycoproteins was developed in 2003 [46], and the strains
of our genotype pools have contributed to the development of
this system for genotypes 1b, 2a, 3a, 4a, 5a, and 6a [30, 47].
In 2005, the JFH1 (genotype 2a)–based cell culture system
was developed; this system provides robust HCV infection in
Huh7.5 cells [10]. The genotype pools presented here have
served as the virus source for the development of JFH1-based
intragenotypic and intergenotypic recombinants of genotypes
1b, 2a, 2b, 3a, 4a, 5a, and 6a, producing viruses with the ge-
notype-specific core, E1, E2, p7, and NS2 in Huh7.5 cells [29,
31, 32, 48, 49]. Thus, the virus genotype pools have contributed
to the development of new experimental systems for HCV. The
use of prototype strains in the development of such systems
provides the added advantage of permitting the use of identical
HCV strains in different experimental systems. For example,
antibodies identified in vitro in the HCV pseudoparticle systems
or in the JFH1-based cell culture systems could be used for
passive immunoprophylaxis studies with chimpanzees in which
a matched challenge virus from the genotype pools is used.
In the human liver–uPA-SCID mouse model, we observed
robust infection with HCV strains that represent HCV geno-
types 1–6, in most cases with peak HCV RNA titers that were
1log10–3log10 higher than those observed for the same strains
in chimpanzees. Robust infection was seen in mice with dif-
ferent human liver grafts, but titration data indicated that HCV
infectious doses that are 1–2 logs higher than those required
to infect chimpanzees are required to infect human liver–chi-
meric mice. Plasma from infected mice with relatively high
HCV RNA titers (often of 1107 IU/mL; Table 3) can be used
to make additional antibody-free challenge pools of these HCV
strains, as we reported for the H77C strain [16]. The suscep-
tibility of the human liver–chimeric mice to well-defined chal-
lenge viruses will permit more detailed studies of the cross-
neutralization potential of antibody preparations. In addition,
new drugs can be tested for therapeutic potential against the
different genotypes [14–16, 50].
In summary, we have developed titrated challenge pools of
genotypes 1–6 of HCV. These reference viruses are available to
the scientific community and will contribute to studies of active
and passive immunity against HCV. In addition, these challenge
pools of genotypes 1–6 will permit controlled studies in vitro
and in vivo, because different experimental systems have already
been developed for these strains: for the HC-J6 (genotype 2a)
strain, a consensus molecular clone that is infectious for chim-
panzees, a retroviral pseudoparticle system that permits entry
into Huh7 cells, and a JFH1-based intragenotypic recombinant
that is infectious for Huh7 cells have been developed [28, 30,
47, 49]. We have demonstrated that infection of chimpanzees
with all HCV genotypes resulted in relatively high HCV titers
and liver inflammation, and that viruses from the challenge
genotype pools readily infect human liver–chimeric mice, which
will permit further studies with both animal models of HCV
infection.
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